FTSE MIB
28.575,90 -132,65 (-0,46%) Dow Jones
33.963,84 -106,58 (-0,31%) Nasdaq
13.211,81 -12,18 (-0,09%) Nikkei 225
32.402,41 -168,62 (-0,52%) Petrolio
90,33 +0,70 (+0,78%) Bitcoin EUR
24.960,76 -5,99 (-0,02%)
Biocartis Group NV (0R72.L)
| Chiusura precedente | 1,7197 |
| Aperto | 1,7197 |
| Denaro | N/D x N/D |
| Lettera | N/D x N/D |
| Min-Max giorno | 1,7200 - 1,7200 |
| Intervallo di 52 settimane | 0,2865 - 1,7200 |
| Volume | |
| Media Volume | 75.678 |
| Capitalizzazione | N/D |
| Beta (5 anni mensile) | 1,38 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | N/D |
| Prossima data utili | N/D |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswirePress release Biocartis Group NV: Biocartis 2023 half-year results webcast on 26 September 2023
PRESS RELEASE REGULATED INFORMATION 21 September 2023, 07:00 CEST BIOCARTIS 2023 HALF-YEAR RESULTS WEBCAST ON 26 SEPTEMBER 2023 Mechelen, Belgium, 21 September 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), will report its 2023 half-year results and provide further updates on the status of its reorganization and financing & recapitalization plans on 26 September 2023 at 07:00 CEST. That day, Roger Moody, Biocartis
- GlobeNewswire
Press Release Biocartis Group NV: Biocartis appoints new Medical Advisory Board (MAB) of renowned practice leaders
PRESS RELEASE: 28 August 2023, 7:00 AM CEST Biocartis appoints new Medical Advisory Board (MAB) of renowned practice leaders Mechelen, Belgium, 28 August 2023 - Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), is pleased to announce the appointment of a global Medical Advisory Board (MAB) comprised on renowned and influential KOLs in diagnostics, pharma and hospitals to advise, inform and guide Biocartis’ expedited global
- GlobeNewswire
Press Release Biocartis Group NV: Biocartis Announces 2023 Half-Year Results on 26 September 2023
PRESS RELEASE: 24 August 2023, 07:00 CEST BIOCARTIS ANNOUNCES 2023 HALF-YEAR RESULTS ON 26 SEPTEMBER 2023 Mechelen, Belgium, 24 August 2023 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), announces today that it will report its 2023 half-year results and provide further updates on the status of its reorganization and financing & recapitalization plans on 26 September 2023, which is later than the previously communicated
